AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00735449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%
Description: 1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
Study NCT00735449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol maleate 0.5%
Description: 1 drop of timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
Study NCT00735449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005%
Description: 1 drop of latanoprost 0.005% once nightly.
Study NCT03251560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuke Qianjin capsule
Description: Fuke Qianjin capsule 0.8g pills by mouth, three times daily
Study NCT03251560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule 0.8g pill by mouth, three times daily
Study NCT01040403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medium tiotropium bromide
Description: medium tiotropium bromide
Study NCT01040403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high tiotropium bromide
Description: high tiotropium bromide
Study NCT04343222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac
Description: An NSAID used to treat eye pain and swelling
Study NCT04343222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artificial tears
Description: eye drops to lubricate the eye and maintain moisture
Study NCT01040403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT04343222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tears
Description: eye drops to lubricate the eye and maintain moisture
Study NCT03664219 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isolation of IAN from implant with collagen membrane
Description: comparing between the neurosensory disturbances with and without isolation of the inferior alveolar nerve from implant
Study NCT03664219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isolation of IAN from implant with collagen membrane
Description: comparing between the neurosensory disturbances with and without isolation of the inferior alveolar nerve from implant
Study NCT01800708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Study NCT01040403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: Respimat inhaler
Study NCT01800708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone syrup
Study NCT01297530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY87-2243
Description: Oral administration once daily in a continuous schedule. Starting dose will be 5 mg and dose will be escalated dependent on any dose limiting toxicities.
Study NCT00309608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Linagliptin medium dose tablet once daily
Study NCT00309608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Linagliptin high dose tablet once daily
Study NCT00309608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Linagliptin low dose tablet once daily
Study NCT00309608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once daily
Study NCT00309608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride tablets once daily
Study NCT03424720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PLE and BIS
Description: Investigators attach the PLE and BIS sensors on the forehead of the patients undergoing facial nerve integrity monitoring during general anesthesia using total intravenous anesthetics
Study NCT04013490 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cassava dietary fiber capsule
Description: Cassava dietary fiber capsule or placebo will be consumed once daily at the recommended doses of each group.
Study NCT04013490 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cassava dietary fiber capsule
Description: Cassava dietary fiber capsule or placebo will be consumed once daily at the recommended doses of each group.
Study NCT06250543 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AbobotulinumtoxinA 300 UNT
Description: 20 evenly distributed intradetrusor injections, 1 ml per site, were performed
Study NCT06250543 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IncobotulinumtoxinA 100 UNT
Description: 20 evenly distributed intradetrusor injections, 1 ml per site, were performed
Study NCT06250543 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lidocain
Description: 30 minutes before the procedure the bladder was instilled with 40 ml of 1% lidocaine solution using a 16Fr urethral Foley catheter
Study NCT06250543 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: placebo
Description: 30 minutes before the procedure the bladder was instilled with 40 ml of 0.9% NaCl solution
Study NCT03402373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycoderm
Description: soft gel contains nutritional supplement
Study NCT03402373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: soft gel without active ingredients
Study NCT02089815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home based exercise
Description: modified Otago exercise program to simple designed home based exercise program
Study NCT02089815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fall prevention education and counseling
Study NCT02089815 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fall prevention education and counseling
Study NCT02274649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: one-to-one peer mentoring
Description: Each patient received one-to-one peer mentoring each week during rehabilitation and for 90 days post discharge
Study NCT02274649 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: general peer support
Description: General (traditional) peer support includes introduction and provision of support services upon request
Study NCT04394091 — intervention group
Intervention type: DEVICE
Intervention: ultrasensitive PET CT
Description: A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER), has been constructed to offer a transformative platform for human radiotracer imaging in clinical research and healthcare. Its total-body coverage and exceptional sensitivity provide opportunities for innovative studies of physiology, biochemistry, and pharmacology.
Study NCT02610218 — intervention group
Intervention type: OTHER
Intervention: CTC and cfDNA analysis
Description: The enumeration of CTCs as well as the detection of HER2 expression will be achieved via the integrated subtraction enrichment (SET) and immunostaining-fluorescence in situ hybridization (iFISH) platform. Further, for the geneomic analysis, the enriched single CTC will be isolated for single-cell targeted sequencing. While for cfDNA analysis, extracted DNA from plasma will be directly subjected to targeted sequencing. Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
Study NCT04623411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neonatal resuscitation training with classical method and serious game simulation method
Description: After the theoretical training, the participants will be given technical information on the use of web-based neonatal resuscitation serious game simulation method.~Each participant will be asked to apply this method at least three times.
Study NCT04623411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Neonatal resuscitation training with classical method
Study NCT01099540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib 800 mg qd daily
Study NCT00063817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning Regimen
Description: Cyclophosphamide 60 mg per kilogram (kg) of body weight per day intravenously (IV) on days -5 and -4 with respect to transplantation; humanized anti-CD2 monoclonal antibody (MEDI-507) 0.6 mg per kg on days -1, 0, and 1 (after test dose of 0.1 mg per kg on day -2); and cyclosporine A 5 mg per kg IV and thymic irradiation (700 cGy) on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered postoperatively, 8 to 12 mg per kg per day, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months. Protocol amendment that applied to participant 4 and 5: rituximab, 375 mg per square meter of body-surface area days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days.
Study NCT02045433 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR Boost Therapy
Description: 1. Initial Pelvic (+/- Para-aortic) fractionated external beam Radiation with 45 Gy to combined PTV with a boost to 55Gy for PET positive/CT enlarged nodes;~2. Image Guided Hypofractionated Radiation Treatment boost to Cervix High risk CTV/PTV 28GY/4 fx.~Patients will receive 4 fractions of 7 Gy each via stereotactic body radiation as boost therapy to a volume that encompasses the cervical tumor. A minimum of 40 hours should separate each treatment.
Study NCT03085251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring systems for self-testing (BGMS)
Description: Measurement procedure~* Subjects will be asked to wash and dry their hands before the measurements.~* The measurement procedure for each reagent system lot of a BGMS will be as follows:~* Study personnel will collect a capillary blood sample from the subject's fingertip by skin puncture.~* Duplicate measurements on the sample will be consecutively performed with 2 test meters using reagent system units from the same vial / package.~* Capillary blood for measurements with all 3 test strip lots and for both comparison measurements will be taken from the same finger puncture.~* The sample will be applied to the reagent system units following specifications in the manufacturer's labelling.
Study NCT01807871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch, experimental use
Description: nicotine patch-transdermal, continue during lapses Nicotine patches are used according to normal package label, except if the participant lapses and smokes, they will continue to use the patch.
Study NCT01807871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine patch, labeled use
Description: nicotine patch-transdermal, discontinue during lapses Participants will use the nicotine patch while abstinent, but will remove the patch if there is a lapse and smoking resumes. This is the use indicated on current FDA approved labeling.
Study NCT01946347 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mixed meal
Description: Baguette Cheese Gourmet (Crocodile:~180g, energy 452.8 Kcal, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g.
Study NCT01946347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mixed meal
Description: Baguette Cheese Gourmet (Crocodile:~180g, energy 452.8 Kcal, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g.
Study NCT01946347 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute in vivo induced hyperinsulinemia
Description: Hyperinsulinemic (1mU/kg/min) euglycemic clamp 3 hours long
Study NCT01946347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute in vivo induced hyperinsulinemia
Description: Hyperinsulinemic (1mU/kg/min) euglycemic clamp 3 hours long
Study NCT03711955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Two types of training exercises, AET and IRT, will be used as the interventions in this study. Participants will either be assigned to the AET group or the IRT group, where they will participate in the respective training intervention group for 8 consecutive weeks.
Study NCT00783406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00610355
Description: dry powder inhaler, 1472 mcg, single dose
Study NCT00783406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00610355
Description: dry powder inhaler, 736 mcg, single dose
Study NCT00783406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00610355
Description: dry powder inhaler, 368 mcg, single dose
Study NCT00783406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02253277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib was supplied by Novartis as 150 mg and 200 mg hard gelatin capsules. Nilotinib was not dosed by weight or body surface area. Medication labels were in German and complied with the legal requirements of Germany. They included storage conditions for the drug but no information about the patient. The investigator emphasized compliance and instructed the patient to take nilotinib exactly as prescribed.
Study NCT02253277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib was supplied by Novartis as 5 mg, 15 mg, and 20 mg tablets. Medication labels were in German and complied with the legal requirements of Germany. They included storage conditions for the drug but no information about the patient. The investigator emphasized compliance and instructed the patient to take ruxolitinib exactly as prescribed.
Study NCT02634060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Based Fecal Calprotectin
Description: Home Based Fecal Calprotectin measurement at weeks 0, 4 and 8
Study NCT00600795 — intervention group
Intervention type: OTHER
Intervention: CSF collection
Description: CSF collection at time of VPS insertion
Study NCT02158936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag will be round film-coated tablets containing eltrombopag equivalent to 50 mg (white to off-white), 200 mg and 300 mg (green) of eltrombopag free acid
Study NCT02158936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous Injection (IV if local standard)
Study NCT02158936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Description: Subcutaneous Injection (IV if local standard)
Study NCT02158936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eltrombopag matching placebo tablets
Study NCT02158936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eltrombopag matching placebo tablets will be supplied
Study NCT01943071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Day care for patients with dementia
Description: Day care centres designed by the local authorities for patients with dementia
Study NCT03966170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: Citicoline as neuroprotector
Study NCT03966170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: placebo drug
Study NCT04253431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Droplet lancing device (HTL-Strefa S.A.)
Study NCT04253431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microlet 2 lancing device (Bayer)
Study NCT04253431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch Delicia lancing device (LifeScan)
Study NCT04253431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReliOn lancing device (ReliOn)
Study NCT04253431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek Softclix lancing device (Roche)
Study NCT04253431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BGStar lancing device (Sanofi Aventis)
Study NCT04253431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra-Fine 33G lancets (BD)
Study NCT04253431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Droplet 33G lancets (HTL-Strefa S.A.)
Study NCT04253431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch Delicia Extra Fine 33G lancets (LifeScan)
Study NCT04253431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HaemoFine 33G lancets (HTL-Strefa S.A.)
Study NCT04253431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Softclix 28 G lancets (Roche)
Study NCT04253431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReliOn Ultra-Thin Plus 33G lancets (ReliOn)
Study NCT01585350 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MELITAC 12.1 + Montanide ISA-51 + polyICLC
Description: Cohort 2 will be divided into three sub-groups and will receive:~* Group 2a: MELITAC 12.1 + polyICLC adjuvant~* Group 2b: MELITAC 12.1 + polyICLC adjuvant + Montanide adjuvant with vaccination #1~* Group 2c: MELITAC 12.1 + polyICLC adjuvant + Montanide adjuvant with all vaccinations
Study NCT01759810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes
Study NCT01759810 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes
Study NCT01756781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Treatment A includes a single 2 mg oral dose of midazolam alone. Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.
Study NCT01756781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: Treatment B includes 8 daily 125 mg oral doses of PD-0332991.
Study NCT01756781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.~Treatment A includes a single 2 mg oral dose of midazolam alone.
Study NCT01756781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991.
Study NCT04781829 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BioFire Pneumonia Panel
Description: Treatment based on an algorithm that recommends antibiotic choices based on bacteria/virus detected by BioFire Pneumonia Panel
Study NCT02707406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEOX®CORD 1K
Description: use of human tissue product wound covering
Study NCT02707406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard of care
Description: standard wound coverings
Study NCT02707406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: standard wound coverings
Study NCT03119623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sacubitril/valsartan
Description: Sacubitril/valsartan 100mg titrated up to sacubitril/valsartan 200mg
Study NCT03119623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: enalapril 5mg, titrated up to 10mg po BID
Study NCT03811288 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
Study NCT04161079 — intervention group
Intervention type: DEVICE
Intervention: Medtentia Annuloplasty Ring (MAR)
Description: Mitral valve repair using the MAR performed in clinical investigation 2010-040
Study NCT01985438 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous endoscopic gastrostomy tube placement
Description: A 20 Fr PEG tube (Cook Medical, or Boston Scientific) will be placed endoscopically using Ponsky's pull technique, under conscious sedation, as a day-case procedure. A single dose of a prophylactic intravenous antibiotic (1.2g co-amoxiclav, 30 minutes prior to the procedure, unless evidence of penicillin allergy) will be given to all patients undergoing PEG tube insertion. Patients will be monitored for one hour prior to discharge following PEG tube insertion.
Study NCT01985438 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nasogastric tube placement
Description: All nasogastric tubes will be inserted in a standard manner by a Gastroenterology Fellow or an Internal Medicine resident. Ordinarily, a 14 Fr, fine-bore NG feeding tube will be inserted at the bedside or, if unsuccessful, inserted under radiological guidance. A post-procedure abdominal x-ray will be performed to confirm correct placement of all NG tubes.